Solid dispersion of prednisolone: Solid state characterization and improvement of dissolution profile

Drug Development and Industrial Pharmacy

Volumn 37, Issue 4, 2011, Pages 373-386

  Palanisamy, Mohanraj ^a   Khanam, Jasmina ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Dissolution enhancement; prednisolone; solid dispersion; solubility; wettability

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; DRUG CARRIER; MACROGOL; POLYVINYLPYRROLIDONE CO VINYL ACETATE; POVIDONE; PREDNISOLONE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DISSOLUTION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; FOURIER TRANSFORM MASS SPECTROMETRY; IN VITRO STUDY; SOLID DISPERSION; SOLID STATE; THERMAL ANALYSIS; THERMOGRAPHY; WETTABILITY; X RAY DIFFRACTION;

BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG STABILITY; MATHEMATICS; PREDNISOLONE; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 79953253187     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.513984     Document Type: Article

References (45)

1. Dubin CH. (2006). Formulation strategies for poorly soluble drugs. Drug Deliy Technol, 6:34-6.
2. Lipinski CA. (2000). Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol, 44:235-49. (Pubitemid 32239479)
3. Scholz A, Abrahamsson B, Diebold SM, Kostewicz E, Polentarutti BI, Ungell AL, et al. (2002). Influence of hydrodynamics and particle size on the absorption of felodipine in Labradors. Pharm Res, 19:42-6. (Pubitemid 34075105)
4. Liversidge EM, Liversidge GG, Cooper ER. (2003). Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci, 18:113-20. (Pubitemid 36184748)
5. Takeuchi H, Nagira S, Yamamoto H, Kawashima Y. (2005). Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int J Pharm, 293:155-64. (Pubitemid 40381089)
6. Stella VJ, Martodihardjo S, Rao VM. (1999).Aqueous solubility and dissolution rate does not adequately predict in vivo performance: A probe utilizing some N-acyloxymethyl phenytoin prodrugs. J Pharm Sci, 88:775-79. (Pubitemid 29398544)
7. Stegemann S, Leveiller F, Franchi D, Jong HD, Linden H. (2007). When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci, 3:249-61. (Pubitemid 47079001)
8. Leuner C, Dressman J. (2000) Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm, 50:47-60. (Pubitemid 30326688)
9. Serajuddin ATM. (1999). Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci, 88:1058-1066.
10. Urbanetz NA, Lippold BC. (2005). Solid dispersions of nimodipine and polyethylene glycol 2000: Dissolution properties and physico-chemical characterization. Eur J Pharm Biopharm, 59:107-18. (Pubitemid 39573442)
11. Okonogi S, Oguchi T, Yonemochi E, Puttipipatkhachorn S, Yamamoto K.(1997). Improved dissolution of ofloxacin via solid dispersion. Int J Pharm, 156:175-180. (Pubitemid 27400005)
12. Pan RN, Chen JH, Chen RRL. (2000). Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems. Drug Dev Ind Pharm, 26:989-94.
13. Wong JW, Yuen KH. (2001). Improved oral bioavailability of Artemisinin through inclusion complexation with â- and ã- cyclodextrins. Int J Pharm, 227:177-85. (Pubitemid 32868771)
14. Vogt M, Derendorf H, Krämer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM.(2007). Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone. J Pharm Sci, 96:27-37. (Pubitemid 46087336)
15. Barnes PJ. (1998). Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci, 94:557-572. (Pubitemid 28269054)
16. Sahin NO, Arslan H. (2007). Inclusion complex of prednisolone with skimmed milk Part I: Physicochemical characterization. Yakugaku Zasshi, 127:1255-61. (Pubitemid 47204005)
17. Fukuda N, Higuchi N, Ohno M, Kenmochi H, Sekikawa H, Takada M (1986). Dissolution behavior of prednisolone from solid dispersion systems with cyclodextrins and polyvinylpyrrolidone. Chem Pharm Bull, 34:1366-9. (Pubitemid 16103754)
18. Jachowicz R (1987). Dissolution rates of partially water-soluble drugs from solid dispersion systems. I. Prednisolone. Int J Pharm, 35:1-5. (Pubitemid 17016872)
19. Khan GM, Jiabi Z. (1998). Preparation, characterization, and dissolution studies of ibuprofen solid dispersions using polyethylene glycol dispersion carrier's PEG, talc, and PEG-talc. Drug Dev Ind Pharm, 24:455-62. (Pubitemid 28273136)
20. Valizadeh H, Nokhodchi A, Qarakhani N, Milani PZ, Azarmi S, Hassanzadeh D, Lobenberg R. (2004). Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, myrj 52, lactose, sorbitol, dextrin, and eudragit E100. Drug Dev Ind Pharm, 30:303-17. (Pubitemid 38451755)
21. Janssens S, Armas HND, Roberts CJ, Mooter GVD. (2008). Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5. J Pharm Sci, 97:2110-20.
22. Fernandes CM, Vieira MT, Veigaa FJB.(2002). Physicochemical characterization and in vitro dissolution behavior of nicardipine- cyclodextrins inclusion compounds. Eur J Pharm Sci, 15:79-88. (Pubitemid 34136971)
23. Liu C, Desai KG. (2005). Characteristics of rofecoxib-polyethylene glycol 4000 solid dispersions and tablets based on solid dispersions. Pharm Dev Tech, 10:467-77. (Pubitemid 41770031)
24. Zajc N, Obreza A, Bele M, Srcic S. (2005). Physical properties and dissolution behaviour of nifedipine/mannitol solid dispersions prepared by hot melt method. Int J Pharm, 291:51-58. (Pubitemid 40221996)
25. Indian Pharmacopoeia (2007). Published by Government of India, Vol - II, 1584.
26. Moore JW, Flanner HH. (1996).Mathematical comparison of dissolution profiles. Pharm Tech, June: 64-75.
27. Jun SW, Kim MS, Kim JS, Park HJ, Lee S, Woo JS, et al. (2007). Preparation and characterization of simvastatin/hydroxypropyl- â-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm, 66:413-21. (Pubitemid 46756217)
28. Mukne AP, Nagarsenker MS. (2004). Triamterene-â-cyclodextrin systems: Preparation, characterization and in vivo evaluation. AAPS Pharm Sci Tech, 5(1) Article 19:1-9.
29. Valle EMMD. (2004). Cyclodextrins and their uses: A review. Process Biochem, 39:1033-46.
30. Omari MMA, Zughul MB, Davies JED, AA Badwan. (2006). Sildenafil/ cyclodextrin complexation: Stability constants, thermodynamics, and guest-host interactions probed by 1H NMR and molecular modeling studies. J Pharm Biomed Anal, 41:857-65.
31. Hilton JE, Summers MP. (1986). The effect of wetting agents on the dissolution of indomethacin solid dispersion systems. Int J Pharm, 31:157-64. (Pubitemid 16057427)
32. Bhandari BR, Arcy BRD, Padukka I. (1999). Encapsulation of lemon oil by paste method using â-cyclodextrin: Encapsulation efficiency and profile of oil volatiles. J Agric Food Chem, 47:5194-7. (Pubitemid 30016960)
33. Shah M, Karekar P, Sancheti P, Vyas V, Pore Y. (2009). Effect of PVP K30 and/or l-arginine on stability constant of etoricoxib-HPâCD inclusion complex: Preparation and characterization of etoricoxib- HPâCD binary system. Drug Dev Ind Pharm, 35:118-29.
34. Uzqueda M, Mart€n C, Zornoza A, Sanchez M, Oharriz MCM, Velaz I. (2006). Characterization of complexes between naftifine and cyclodextrins in solution and in the solid state. Pharm Res, 23:980-8. (Pubitemid 43781406)
35. Mura P, Faucci MT, Bettinetti GP (2001). The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl- â-cyclodextrin. Eur J Pharm Sci, 13:187-194. (Pubitemid 32288788)
36. Diaz MTE, Labandeira JJT, Kata M, Jato JLV. (1994). Inclusion complexation of glibenclamide with 2-hydroxypropyl-â-cyclodextrin in solution and in solid state. Eur J Pharm Sci, 1:291-6. (Pubitemid 24208431)
37. Arias MJ, Moyano JR, Gines JM. (1997). Investigation of the triamterene- â-cyclodextrin system prepared by co grinding. Int J Pharm, 153:181-9.
38. Craig DQM. (2002).The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm, 231:131-44. (Pubitemid 34033673)
39. Heo MY, Piao ZZ, Kim TW, Cao QR, Kim A, Lee BJ. (2005). Effect of solubilizing and micro emulsifying excipients in polyethylene glycol 6000 solid dispersion on enhanced dissolution and bioavailability of ketoconazole. Arch Pharm Res, 28:604-11. (Pubitemid 44698739)
40. Cirri M, Maestrelli F, Corti G, Mura P, Valleri M. (2007). Fast-dissolving tablets of glyburide based on ternary solid dispersions with PEG 6000 and surfactants. Drug Deliv, 14:247-55. (Pubitemid 46752408)
41. Costaa FO, Sousaa JJS, Paisb AACC, Formosinho SJ. (2003). Comparison of dissolution profiles of ibuprofen pellets. J Control Release, 89:199-212. (Pubitemid 36507015)
42. Patterson JE, James MB, Forster AH, Rades T (2008). Melt extrusion and spray drying of carbamazepine and dipyridamole with polyvinylpyrrolidone/vinyl acetate copolymers. Drug Dev Ind Pharm, 34:95-106. (Pubitemid 351156956)
43. Weuts I, Kempen D, Verreck G, Decorte A, Heymans K, Peeters J, et al. (2005) Study of the physicochemical properties and stability of solid dispersions of loperamide and PEG 6000 prepared by spray drying. Eur J Pharm Biopharm, 59:119-26. (Pubitemid 39573443)
44. Maitre MM, Longhi MR, Granero GG. (2007). Ternary complexes of flurbiprofen with HP-â-CD and ethanol amines characterization and transdermal delivery. Drug Dev Ind Pharm, 33:311-26. (Pubitemid 46650745)
45. Patel RP, Patel MM (2007). Physicochemical characterization and dissolution study of solid dispersions of lovastatin with polyethylene glycol 4000 and polyvinylpyrrolidone K30. Pharm Dev Tech, 12:21-33. (Pubitemid 46902607)